CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today reported continued progress in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results